1 / 7

Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96. Baseline Characteristics of the 2342 Study Subjects. Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96.

havard
Télécharger la présentation

Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  2. Baseline Characteristics of the 2342 Study Subjects Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  3. Baseline Levels of OxLDL Biomarkers [Mean (95% CI)] in Patients With Various Cardiovascular Risk Factors and According to Median Lipid Profile Values on Presentation Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  4. Change in OxPL/apoB and Lp(a) Levels in Various Subgroups in Response to Atorvastatin The panels represent the mean percent change (95% confidence interval) from baseline to week 16 in OxPL/apoB (A) and Lp(a) (B) levels in the various subgroups according to treatment with atorvastatin versus placebo. The p values listed in the right margin in each panel represent differences between placebo versus atorvastatin in the various subgroups. ‡Within-group mean percent changes from baseline to week 16 in the placebo or atorvastatin groups individually (‡p<0.001). OxPL/apoB = oxidized phospholipids as measured by antibody E06. Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  5. Within-Group Changes in the Mean Percent Change From Baseline in Immune Complexes and Autoantibodies to MDA-LDL [Mean (95% CI)] Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  6. Correlations Among OxLDL Biomarkers at Randomization Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

  7. Correlation Between OxLDL Biomarkers With Lipid Parameters and Inflammatory Markers at Randomization Fraley AE, et al. J Am Coll Cardiol 2009;53:2186-96

More Related